{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05687344",
            "orgStudyIdInfo": {
                "id": "PRO00046214"
            },
            "organization": {
                "fullName": "Medical College of Wisconsin",
                "class": "OTHER"
            },
            "briefTitle": "Intensive Postpartum Antihypertensive Treatment",
            "officialTitle": "Intensive Postpartum Antihypertensive Treatment to Improve Women's Cardiovascular Health (IPAT Study)",
            "acronym": "IPAT",
            "therapeuticArea": [
                "Women's Health"
            ],
            "study": "intensive-postpartum-antihypertensive-treatment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-01",
            "studyFirstSubmitQcDate": "2023-01-16",
            "studyFirstPostDateStruct": {
                "date": "2023-01-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Anna Palatnik, MD",
                "investigatorTitle": "Associate Professor",
                "investigatorAffiliation": "Medical College of Wisconsin"
            },
            "leadSponsor": {
                "name": "Medical College of Wisconsin",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.",
            "detailedDescription": "The IPAT will randomize 60 postpartum patients with HDP at the Medical College of Wisconsin (MCW) to intensive BP control with Nifedipine extended release (ER) (target BP \\<140/90 mmHg) versus usual care (target BP \\<160/110 mmHg). Oversampling of Black patients with HDP will be done to ensure they comprise 50% of study participants. Patients enrolled in both arms will undergo education on healthy lifestyle following AHA \"Life's Essential 8\" (LE8) of tobacco cessation, physical activity, healthy sleep, and healthy diet with detailed overview of DASH throughout the first year postpartum with monthly virtual educational session delivered by a registered dietician and a life coach. Assessment of LE8 CVH score will be done after delivery, 6 weeks postpartum, and 12 months postpartum. Participants will also undergo vascular function assessment: endothelial dysfunction with brachial artery flow mediated dilation (FMD), arterial stiffness with carotid-femoral pulse wave velocity (cfPWV) and anti-angiogenic and inflammatory CVD biomarker with soluble fms-like tyrosine kinase (sFlt-1), at baseline, 6 weeks, and 12 months postpartum. The primary outcome is feasibility of all study procedures, including recruitment, retention, and adherence. Secondary outcomes are change in BP, CVH score, FMD, PWV, and sFlt-1 from baseline to 12 months postpartum."
        },
        "conditionsModule": {
            "conditions": [
                "Hypertensive Disorder of Pregnancy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intervention arm",
                    "type": "EXPERIMENTAL",
                    "description": "Intervention group - intensive postpartum BP control with Nifedipine initiation at SBP\u2265140 mmHg or DBP\u226590 mmHg and maintaining BP at \\<140/90 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.",
                    "interventionNames": [
                        "Drug: Nifedipine ER"
                    ]
                },
                {
                    "label": "Active control arm",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Active control group - a group of usual care that follows ACOG recommendations with Nifedipine initiation at SBP\u2265150 mmHg or DBP\u2265100 mm Hg and maintaining BP at \\<150/100 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.",
                    "interventionNames": [
                        "Drug: Nifedipine ER"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Nifedipine ER",
                    "description": "Postpartum BP treatment to \\<140/90 mmHg",
                    "armGroupLabels": [
                        "Active control arm",
                        "Intervention arm"
                    ],
                    "otherNames": [
                        "Tight BP control group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Feasibility in randomization",
                    "description": "Proportion of patients who enroll out of all approached, eligible patients.",
                    "timeFrame": "12 months postpartum"
                },
                {
                    "measure": "Feasibility in recruitment",
                    "description": "Number of patients successfully enrolled per month during the study.",
                    "timeFrame": "12 months postpartum"
                },
                {
                    "measure": "Feasibility in retention",
                    "description": "Proportion of enrolled patients who complete all study visits during the 12 months follow-up.",
                    "timeFrame": "12 months postpartum"
                },
                {
                    "measure": "Contamination",
                    "description": "Percent of patients following other antihypertensive treatment regimens.",
                    "timeFrame": "12 months postpartum"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "New stage I hypertension",
                    "description": "BP of \u2265130/80 mmHg",
                    "timeFrame": "12 months postpartum"
                },
                {
                    "measure": "Life's Essential 8 cardiovascular health score (range 0-100)",
                    "description": "The score will be calculated using American Heart Association application",
                    "timeFrame": "12 months postpartum"
                },
                {
                    "measure": "Life's Simple 7 CVH (range 0-14)",
                    "description": "Same metrics as LE8 excluding sleep",
                    "timeFrame": "12 months postpartum"
                },
                {
                    "measure": "Flow-mediated dilation",
                    "description": "Brachial artery flow-mediated dilation will assess endothelial dysfunction.",
                    "timeFrame": "12 months postpartum"
                },
                {
                    "measure": "Serum biomarkers of CVD risk",
                    "description": "Anti-angiogenic marker: Soluble fms-like tyrosine kinase (sFlt-1)",
                    "timeFrame": "12 months postpartum"
                },
                {
                    "measure": "arterial stiffness",
                    "description": "Carotid-femoral pulse wave velocity will assess arterial stiffness",
                    "timeFrame": "12 months postpartum"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* HDP diagnosis (gestational hypertension or preeclampsia) according to ACOG guidelines\n* Postpartum day 0-3 and prior to discharge\n* Able to communicate in English or in Spanish\n* Age 18 - 45\n\nExclusion Criteria:\n\n* Pre-gestational hypertension\n* Pre-gestational diabetes ( type 1 or type 2)\n* Intent to transfer postpartum to an outside institution of the participating centers\n* Known allergy to nifedipine or other significant contraindication to nifedipine\n* Inability or unwillingness to provide informed consent",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Anna Palatnik, MD",
                    "role": "CONTACT",
                    "phone": "4148056627",
                    "email": "apalatnik@mcw.edu"
                },
                {
                    "name": "Zaira Peterson",
                    "role": "CONTACT",
                    "phone": "(414) 805-6622",
                    "email": "zpeterson@mcw.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Froedtert Hospital",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014115",
                    "term": "Toxemia"
                },
                {
                    "id": "D000006973",
                    "term": "Hypertension"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "asFound": "Hypertensive Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16869",
                    "name": "Toxemia",
                    "asFound": "Hypertensive Disorders of Pregnancy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20864",
                    "name": "Sepsis",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009543",
                    "term": "Nifedipine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002121",
                    "term": "Calcium Channel Blockers"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000077264",
                    "term": "Calcium-Regulating Hormones and Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000014665",
                    "term": "Vasodilator Agents"
                },
                {
                    "id": "D000015149",
                    "term": "Tocolytic Agents"
                },
                {
                    "id": "D000012102",
                    "term": "Reproductive Control Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M12483",
                    "name": "Nifedipine",
                    "asFound": "Marginal zone",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5384",
                    "name": "Calcium Channel Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M17412",
                    "name": "Vasodilator Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17869",
                    "name": "Tocolytic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ChanBlk",
                    "name": "Channel Blockers"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                }
            ]
        }
    },
    "hasResults": false
}